GlaxoSmithKline plc (NYSE:GSK) – Equities research analysts at Jefferies Group issued their FY2022 earnings estimates for GlaxoSmithKline in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford expects that the pharmaceutical company will post earnings of $3.75 per share for the year.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%.

Several other equities analysts also recently issued reports on GSK. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Monday. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, September 21st. ValuEngine downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Barclays raised shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and an average price target of $38.57.

Shares of GlaxoSmithKline (GSK) traded up $0.03 on Wednesday, hitting $38.20. 3,478,233 shares of the company traded hands, compared to its average volume of 5,510,000. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $93,270.00, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 2.36 and a beta of 0.97. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53.

The business also recently declared a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were paid a dividend of $0.5037 per share. The ex-dividend date was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a yield of 5.27%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 154.55%.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The shares were bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.

A number of large investors have recently bought and sold shares of GSK. FMR LLC increased its position in shares of GlaxoSmithKline by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of GlaxoSmithKline by 2.3% in the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after acquiring an additional 293,866 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of GlaxoSmithKline by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its position in shares of GlaxoSmithKline by 7.3% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock worth $341,727,000 after acquiring an additional 569,600 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of GlaxoSmithKline by 2.9% in the second quarter. Northern Trust Corp now owns 3,078,478 shares of the pharmaceutical company’s stock worth $132,743,000 after acquiring an additional 85,830 shares in the last quarter. 9.80% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Analysts Issue Forecasts for GlaxoSmithKline plc’s FY2022 Earnings (GSK)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/analysts-issue-forecasts-for-glaxosmithkline-plcs-fy2022-earnings-gsk/1814643.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.